X4 Pharmaceuticals Inc Stock Price, News & Analysis

Sporos Bioventures has announced the formation of a Strategic Advisory Board (SAB), chaired by Douglas E. Williams, Ph.D. The inaugural members include leading experts in precision oncology and immunology: Keith T. Flaherty, M.D., Bing Yao, Ph.D., and Douglas Hanahan, Ph.D. The SAB will support Sporos in advancing its research portfolio targeting unmet medical needs in cancer and immune diseases. This initiative reflects the company's commitment to innovation and collaboration in drug development.

X4 Pharmaceuticals (Nasdaq: XFOR) announced inducement awards to new employees under the 2019 Inducement Equity Incentive Plan on December 31, 2021. The awards comprise options for 37,650 shares, with an exercise price of $2.40 per share, equal to the closing price on January 4, 2022. The options will vest over four years, with 25% vesting after one year. X4 focuses on developing novel therapies targeting the CXCR4 pathway, particularly for rare diseases. Its lead candidate, mavorixafor, is being evaluated in multiple clinical trials, including a Phase 3 trial for WHIM syndrome.

X4 Pharmaceuticals (Nasdaq: XFOR) recently presented positive findings on mavorixafor at the ASH Annual Meeting. The data indicates that mavorixafor effectively raises white blood cell counts across various diseases, including Chronic Neutropenia and WHIM syndrome, showcasing sustained improvements in infection rates. Notably, mavorixafor has been well tolerated in ongoing clinical trials. A virtual seminar on this topic is scheduled for December 16, 2021. Results from a global Phase 3 trial in WHIM syndrome are expected by Q4 2022.

X4 Pharmaceuticals (Nasdaq: XFOR) announced positive interim results from its ongoing Phase 1b trial of mavorixafor in combination with ibrutinib for patients with Waldenström’s macroglobulinemia (WM) and specific mutations. The trial has achieved a remarkable 100% overall response rate in evaluable patients. After 12 months, patients saw significant reductions in serum IgM levels, with median decreases from 47.2 g/L to 7.73 g/L. Further data, including responses from refractory patients, is expected throughout 2022.

X4 Pharmaceuticals (Nasdaq: XFOR) is set to host a virtual seminar titled “Understanding Primary Immunodeficiencies” on December 16, 2021, at 8:30 a.m. EST. The seminar aims to showcase new clinical data on mavorixafor, their leading candidate for treating immunodeficiencies, particularly in the context of WHIM syndrome. Esteemed guest speakers include experts such as Neal Sondheimer, M.D., and Theresa Tarrant, M.D. The event will also highlight relevant research from the upcoming ASH Annual Meeting. A live webcast will be available on the company's website.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced on December 1, 2021, that its Compensation Committee granted inducement awards to new employees. These awards include options for 17,000 shares and restricted stock units for 25,000 shares under the 2019 Inducement Equity Incentive Plan. The options have a ten-year term with an exercise price of $4.45 per share, vesting over four years. X4 focuses on developing CXCR4-targeted therapies, notably mavorixafor, which is undergoing clinical trials for various immune system diseases.

X4 Pharmaceuticals (Nasdaq: XFOR) announced its participation in the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 11:20 AM ET. The event will feature a fireside chat, which will be available via live webcast on X4's investor website. X4 is focused on developing novel CXCR4-targeted therapies for immune system diseases, with mavorixafor as its lead candidate. The company is advancing mavorixafor through various clinical trials for conditions including primary immunodeficiencies and certain cancers. The archived event will be accessible for 90 days post-conference.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) reported significant advancements in its WHIM syndrome treatment, mavorixafor, including the completion of enrollment in a pivotal Phase 3 trial. The company anticipates top-line data in Q4 2022. Recent findings indicate a potential U.S. WHIM patient population of 3,700, with mavorixafor demonstrating increased neutrophil levels and good tolerability. Financial results show a net loss of $20.2 million for Q3 2021, up from $17.4 million year-over-year. An Investor Day is scheduled for December 16, highlighting further clinical data.

X4 Pharmaceuticals (Nasdaq: XFOR) announced on November 1, 2021, that its Compensation Committee granted inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. The awards include options to purchase 11,050 shares of common stock at an exercise price of $4.84 per share, matching the stock's closing price on October 29, 2021. Options vest over four years, with a quarter vesting after one year. X4 focuses on CXCR4-targeted therapies for immune system diseases, with its lead candidate mavorixafor currently undergoing multiple clinical trials.